NASDAQ NMS - GLOBAL MARKET · ELUT
+0.91% · +$0.0086 · Vol 15.4K
Live · updated 13:03:38 ET
Elutia Inc

Elutia Inc

Biotechnology
$0.9586

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is ELUT moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Elutia Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2020
Employees
26
Country
US

Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.9891
Day high
$1.02
Day low
$0.9400
Previous close
$0.9500
52W high
$1.09
-12.06% from high
52W low
$0.9202
23% of range
Market cap
$42M
P/E
0.84×
EPS
$-0.8300
Shares out
44.2M
Volume
15.4K
VWAP
$0.9726
Price history computed in-house
1W
+2.85%
1M
-7.83%
SMA 50 $0.9822 · below
SMA 200 $0.9822 · below
52W position 23%
Veridion warehouse edge

Warehouse intelligence for ELUT.

Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

ELUT insider activity

Elutia Inc

Score
Coverage building
Pressure
Net buying
Filings
29
Buys / sells
16 / 13
Net value
$141K
Insiders
7
Named filers
MR
Mills C Randal
Insider
Leadership
WL
Williams Michelle LeRoux
Insider
Leadership
FM
Ferguson Matthew
Insider
Leadership
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Net buying: $141K across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Filing dateTrade dateInsiderTitleTypePriceQtyOwnedValueReceipt
2026-06-222026-06-21Mills C RandalInsidersell$1.068,064441,180$9KSEC Form 4
2026-06-122026-06-10Williams Michelle LeRouxInsidersell$1.044,269118,052$4KSEC Form 4
2026-06-122026-06-10Mills C RandalInsidersell$1.049,718426,771$10KSEC Form 4
2026-06-122026-06-10Ferguson MatthewInsidersell$1.044,485480,082$5KSEC Form 4
2026-03-122026-03-10Williams Michelle LeRouxInsidersell$1.094,613109,821$5KSEC Form 4
Full Form 4 history requires Sovereign

Showing 5 recent rows. Sovereign unlocks 24 additional rows, full sorting, and the named-filer history.

Upgrade to Sovereign · $25/mo
Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

ELUT contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ELUT in this window.
Lobbying spend

ELUT lobbying filings, year to date.

Registered lobbying filings matched to Elutia Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ELUT in this window.
Latest news · ELUT
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for ELUT.
Options
Sovereign unlock shows live options positioning for ELUT.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.